Works matching AU Lightbody, Elizabeth D.

Results: 3
    1

    Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55308-5
    By:
    • Nadeem, Omar;
    • Aranha, Michelle P.;
    • Redd, Robert;
    • Timonian, Michael;
    • Magidson, Sophie;
    • Lightbody, Elizabeth D.;
    • Alberge, Jean-Baptiste;
    • Bertamini, Luca;
    • Dutta, Ankit K.;
    • El-Khoury, Habib;
    • Bustoros, Mark;
    • Laubach, Jacob P.;
    • Bianchi, Giada;
    • O'Donnell, Elizabeth;
    • Wu, Ting;
    • Tsuji, Junko;
    • Anderson, Kenneth C.;
    • Getz, Gad;
    • Trippa, Lorenzo;
    • Richardson, Paul G.
    Publication type:
    Article
    2

    An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications.

    Published in:
    FASEB Journal, 2020, v. 34, n. 4, p. 5106, doi. 10.1096/fj.201903117R
    By:
    • Dasgupta, Asish;
    • Chen, Kuang‐Hueih;
    • Wu, Danchen;
    • Hoskin, Victoria;
    • Mewburn, Jeffrey;
    • Lima, Patricia D. A.;
    • Parlow, Leah R. G.;
    • Hindmarch, Charles C. T.;
    • Martin, Ashley;
    • Sykes, Edward A.;
    • Tayade, Chandrakant;
    • Lightbody, Elizabeth D.;
    • Madarnas, Yolanda;
    • SenGupta, Sandip K.;
    • Elliott, Bruce E.;
    • Nicol, Christopher J. B.;
    • Archer, Stephen L.
    Publication type:
    Article
    3